MentionFox
Home › IPO pipeline › Aktis Oncology, Inc.
IPO filings · Form S-1, F-1, 424B4, RW

Aktis Oncology, Inc. IPO

Aktis Oncology, Inc.'s initial public offering: every registration filing, amendment, final prospectus and withdrawal, with the facts quoted from the filings and each one linked.

StatusPriced
TickerAKTS
ExchangeNasdaq Global Select Market
Offering price$18.00
First filed2025-12-19
Filings4

Aktis Oncology, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-12-19. It has amended it 2 times. It filed its final prospectus on 2026-01-09, at a public offering price of $18.00 per share. Each fact below is quoted from the filing named with it.

What the filings say

Listing

Our common stock has been approved for listing on the Nasdaq Global Select Market under the trading symbol “AKTS.”From the 424B4 filed 2026-01-09

Shares offered

We are offering 17,650,000 shares of our common stock.From the 424B4 filed 2026-01-09

Offering price

The public offering price is $18.00 per share.From the 424B4 filed 2026-01-09

Use of proceeds

We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents to:From the 424B4 filed 2026-01-09

Net loss or income

Our net losses for the nine months ended September 30, 2025 and 2024 were $48.6 million and $31.9 million, respectively.From the S-1/A filed 2026-01-07

Timeline

FiledWhat it isFiling
2025-12-19Registration statement filedS-1
2026-01-05Registration statement amendedS-1/A
2026-01-07Registration statement amendedS-1/A
2026-01-09Final prospectus filed: the offering is priced424B4

Tools for this story

Each opens in a new tab, filled in for Aktis Oncology, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.

Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.

Cite this page

Permanent URL: https://mentionfox.com/ipo/aktis-oncology
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Aktis Oncology, Inc. IPO (AKTS, Nasdaq Global Select Market): priced at $18.00 a share. MentionFox, 2026-09-27. https://mentionfox.com/ipo/aktis-oncology